Biotechnology, Pharmaceutical and Life Science Reports and Courses

Main Pages

Best Selling Products

BioNewsCast Press Release Distribution Service

Bioinformatics Market Potential

Vaccine Research & Development 2009

Practical Guide to Finding Partners in Pharma & Biotech, 2nd edition

Royalty Financing Agreements in Pharma, Biotech and Diagnostics

New Products

Advanced Wound Management Pipeline Technology and Market Forecasts to 2015

Artificial Disc Replacement Pipeline Technology and Market Forecasts to 2015

Brazil Anesthesia and Respiratory Devices Market Analysis and Forecasts to 2015

Brazil Orthopedic Devices Market Analysis and Forecasts to 2015

Canada Anesthesia and Respiratory Devices Market Analysis and Forecasts to 2015

Canada Diabetes Care Devices Market Analysis and Forecasts to 2015

Canada Medical Equipment Market Analysis and Forecasts to 2015

Cardiac Assist Devices Pipeline Technology and Market Forecasts to 2015

China Medical Equipment Market Analysis and Forecasts to 2015

Chronic Diseases on the Rise: Personal Health Systems to Play a Key Role in Disease Management

BioPortfolio | Datamonitor Healthcare Reports | Stakeholder Opinions: Pulmonary Arterial Hypertension clinical community builds order from chaos

Stakeholder Opinions: Pulmonary Arterial Hypertension clinical community builds order from chaos

Despite an explosion in the number of drugs and treatment strategies available, pulmonary arterial hypertension is still a rapidly fatal condition for a small, hard to identify patient group. A small clinical elite is currently leading the way in advancing treatment outcomes, and is central to determining which new treatment strategies are used.

Scope

*Defining the key clinical characteristics of the pulmonary arterial sector that present a unique commercial challenge

*Translation of critical clinical issues into pertinent practical considerations for both incumbent players and new market entrants

*Insight into the challenge of determining a patient potential in the context of a miniscule diagnosed population and a phenomenal "at-risk" population

*Assessment of future directions in management and the changing roles of therapies

Highlights

The estimated 8,11516,186 diagnosed pulmonary arterial hypertension patients across the US, Japan, France, Germany, Italy, Spain and the UK represent a fraction of the 28.0135.6 million group known to be at elevated risk. Identifying the true patient potential within known high risk groups remains highly problematic.

A small, but relatively powerful clinical community has brought structure, order and an increasing influence to bear on management through a few specialist centers. This internationally cohesive group has been responsible for laying the foundations for substantial volumes of data pertaining to patients managed in increasingly standardized ways.

A high number of approved and late stage pipeline products, and the increasing exploration of combination therapeutics places a higher emphasis than normal on the perceptions of specialist clinicians, who will increasingly need to triage their attentions to the most promising avenues for improving outcomes.

Reasons to Purchase

*Understand the challenges in aligning product positioning to the demands of the future clinical paradigm

*Identify development strategies that allow optimal buy-in from an increasingly important clinical community

*Qualify market expectations against the practical realities of targeting this fragmented, niche patient population

19-Mar-09 PDF & SlidePack Pages: 134

Table of Contents
Price: $3,800.00 / €2,516.74

BioPortfolio uses RBS Worldpay Secure Server for credit card transactions